|
Variables | | Propensity matching patients | | P value |
Overall (n=40) | Regular hours (n=20) | Off-hours (n=20) |
|
Age (years) | 56.86 (20.57-75.64) | 60.64 (20.57-75.64) | 55.52 (35.18-74.33) | 0.160 |
Sex (male) | 28 (70%) | 13 (65%) | 15 (75%) | 0.490 |
Etiology of Liver Diseases | | | | 0.622 |
HBV | 9 (22.5%) | 4 (20%) | 5 (25%) | |
HCV | 4 (10%) | 2 (10%) | 2 (10%) | |
Alcohol Abuse | 14 (35%) | 7 (35%) | 7 (35%) | |
Drug Related | 2 (5%) | 0 (0%) | 2 (10%) | |
Autoimmune Liver Diseases | 1 (2.5%) | 1 (5%) | 0 (0%) | |
Other or Unclear Etiology | 10 (25%) | 6 (30%) | 4 (20%) | |
Laboratory Tests | | | | |
Red Blood Cell (1012/L) | 2.625 (1.65-3.89) | 2.58 (1.69-3.89) | 2.705 (1.65-3.78) | 0.968 |
Hemoglobin (g/L) | 74.50 (38.00-126.00) | 77.00 (53.00-122.00) | 72.50 (38.00-126.00) | 0.473 |
White Blood Cell (109/L) | 4.40 (1.80-14.90) | 4.40 (2.20-11.70) | 4.35 (1.80-14.90) | 0.839 |
Platelet Count (109/L) | 72.50 (27.00-301.00) | 72.50 (27.00-301.00) | 72.00 (32.00-145.00) | 0.978 |
Total Bilirubin (umol/L) | 18.10 (5.50-106.10) | 16.85 (5.50-50.90) | 18.10 (8.50-106.10) | 0.256 |
Direct Bilirubin (umol/L) | 7.85 (2.20-60.10) | 7.10 (2.20-41.50) | 7.95 (3.00-60.10) | 0.675 |
Indirect Bilirubin (umol/L) | 9.50 (2.80-46.00) | 8.55 (2.80-22.10) | 10.00 (5.40-46.00) | 0.148 |
Albumin (g/L) | 30.65 (18.00-39.20) | 30.85 (19.00-38.60) | 30.00 (18.00-39.20) | 1 |
Alanine Aminotransferase (U/L) | 21.805 (6.79-88.77) | 21.805 (9.44-72.47) | 20.415 (6.79-88.77) | 0.756 |
Aspartate Aminotransferase (U/L) | 25.635 (10.74-136.00) | 28.38 (11.00-88.79) | 25.635 (10.74-136.00) | 0.978 |
Alkaline Phosphatase (U/L) | 80.10 (40.34-234.00) | 80.94 (40.34-234.00) | 78.245 (46.24-149.45) | 0.705 |
Gamma-glutamyl Transpeptidase (U/L) | 41.245 (7.69-295.00) | 40.48 (13.71-254.00) | 42.765 (7.69-295.00) | 0.935 |
Blood Urea Nitrogen (mmol/L) | 7.395 (2.98-18.83) | 7.055 (2.98-18.83) | 8.40 (4.65-18.72) | 0.245 |
Serum Creatinine (umol/L) | 70.11 (34.90-143.10) | 66.68 (42.60-95.20) | 74.255 (34.90-143.10) | 0.117 |
Potassium (mmol/L) | 3.95 (3.10-4.66) | 3.88 (3.10-4.66) | 3.98 (3.27-4.59) | 0.330 |
Sodium (mmol/L) | 139.10 (124.00-145.70) | 138.50 (135.00-141.40) | 139.45 (124.00-145.70) | 0.279 |
PT (seconds) | 15.80 (13.30-24.50) | 15.40 (13.30-23.90) | 16.05 (13.50-24.50) | 0.417 |
APTT (seconds) | 36.25 (30.80-47.50) | 35.90 (30.80-45.20) | 37.15 (32.20-47.50) | 0.351 |
INR | 1.275 (1.02-2.19) | 1.255 (1.08-2.08) | 1.31 (1.02-2.19) | 0.516 |
Child-Pugh Score | 8.00 (5.00-12.00) | 8.00 (5.00-12.00) | 7.00 (5.00-12.00) | 0.836 |
Child-Pugh A/B/C | 14 (35%)/22 (55%)/4 (10%) | 7 (35%)/12 (60%)/1 (5%) | 7 (35%)/10 (50%)/3 (15%) | 0.544 |
MELD Score | 5.82 (-2.38-23.19) | 5.51 (-1.04-14.75) | 6.51 (-2.38-23.19) | 0.245 |
Recalibrated MELD Score | -4.11 (-5.80- -0.51) | -4.17 (-5.53- -2.26) | -3.96 (-5.80- -0.51) | 0.245 |
ALBI Score | -1.67 (-2.62- -0.49) | -1.73 (-2.44- -0.49) | -1.67 (-2.62- -0.60) | 0.787 |
Esophageal Varices (No/Mild/Moderate/Severe) | 2 (5%)/5 (12.5%)/6 (15%)/27 (67.5%) | 1 (5%)/3 (15%)/3 (15%)/13 (65%) | 1 (5%)/2 (10%)/3 (15%)/14 (70%) | 0.971 |
Treatment | | | | |
Endoscopic Treatment | 38 (95%) | 19 (95%) | 19 (95%) | 1 |
Sengstaken Blakemore | 0 (0%) | 0(0%) | 0(0%) | NA |
Somatostatin | 39 (97.5%) | 20 (100%) | 19 (95%) | 0.311 |
Blood Transfusion | 21 (52.5%) | 9 (45%) | 12 (60%) | 0.342 |
PPIs | 40 (100%) | 20 (100%) | 20 (100%) | NA |
Surgery | 0 (0%) | 0 (0%) | 0 (0%) | NA |
5-day Re-bleeding After Treatment | 5 (12.5%) | 2 (10%) | 3 (15%) | 0.633 |
Death During Hospitalization | 1 (2.5%) | 0 (0%) | 1 (5%) | 0.311 |
Length of Stay (days) | 11.95 (5.73-31.06) | 11.95 (5.73-21.95) | 11.28 (7.52-31.06) | 0.441 |
Total Payment (¥) | 24,961.33 (11,212.15-81,125.52) | 25,985.45 (15,513.68-56,952.12) | 24,961.33 (11,212.15-81,125.52) | 0.829 |
|